NASDAQ: URGNUrogen Pharma Ltd Stock
$49.00+1.89 (+4.01%)
Updated Aug 12, 2026
URGN Price
$49.00
Fair Value Price
-$31.63
Market Cap
$2.40B
52 Week Low
$15.86
52 Week High
$49.67
P/E
-24.87x
P/B
-18.09x
P/S
9.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$188.73M
Earnings
-$97.64M
Gross Margin
90.8%
Operating Margin
-43.39%
Profit Margin
-51.7%
Debt to Equity
-2.91
Operating Cash Flow
-$159M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
URGN Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine URGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
URGN
Ranked#44 of 466
Ranked#44 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.90 | A | |
| $112.18 | A | |
| $10.98 | A |
Be the first to know about important URGN news, forecast changes, insider trades & much more!
URGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how URGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
URGN ($49.00) is overvalued by 254.9% relative to our estimate of its Fair Value price of -$31.63 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
URGN ($49.00) is not significantly undervalued (254.9%) relative to our estimate of its Fair Value price of -$31.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
URGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more URGN due diligence checks available for Premium users.
Valuation
URGN fair value
Fair Value of URGN stock based on Discounted Cash Flow (DCF)
Price
$49.00
Fair Value
-$31.63
Undervalued by
254.90%
URGN ($49.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
URGN ($49.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
URGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
URGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.87x
Industry
15.75x
Market
14.4x
URGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-18.09x
Industry
5.8x
URGN's financial health
Profit margin
Revenue
$72.5M
Net Income
-$14.4M
Profit Margin
-19.8%
URGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
URGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$252.6M
Liabilities
$385.0M
Debt to equity
-2.91
URGN's short-term assets ($235.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
URGN's long-term liabilities ($323.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
URGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
URGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$33.0M
Investing
$1.7M
Financing
$500.0k
URGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
URGN vs Biotech Stocks
Urogen Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.